Paladin Labs Inc.

Paladin Labs Inc.

January 24, 2007 07:30 ET

Paladin Labs Announces PravASA® Launch

MONTREAL, CANADA--(CCNMatthews - Jan. 24, 2007) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced the commercial launch of PravASA®, an innovative, cost-effective product which combines pravastatin, a cholesterol-lowering medication, and delayed-release ASA, a platelet aggregation inhibitor, in a single package. PravASA® is a convenient combination package which, based upon a U.S. study, increases patient compliance. In addition, PravASA® offers excellent value for patients who are already being prescribed pravastatin and ASA separately, as PravASA® is priced the same as generic pravastatin. In essence, patients are receiving the benefit of the compliance package with the ASA at no additional cost.

"According to our market research, over 50% of statin prescriptions are written with a prescription for ASA as a preventative measure against heart attacks. PravASA® will be appreciated by patients since they will receive a convenient package including ASA at no additional cost over generic pravastatin. Physicians and provincial formularies will benefit from improved compliance and lower cost to the health system," said Jonathan Ross Goodman, President & CEO of Paladin Labs.

According to IMS Canada, the pravastatin market is valued at approximately $84 million in 2005.

About PravASA®

PravASA® (Pravastatin Sodium and Delayed-Released ASA) is indicated for patients for whom treatment of both pravastatin and ASA is appropriate. Patients treated with PravASA® should also be placed on a standard cholesterol-lowering diet for the duration of the treatment.

Both pravastatin and ASA are indicated for secondary prevention in patients with coronary heart disease. Prevention of recurrent coronary event or death in subjects with established heart disease is known as "secondary prevention." According to the Pubic Health Agency of Canada, heart disease is the leading cause of death for Canadians.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Paladin Web Site at

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2005. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at

Contact Information